Clinical Trials and Research
Patients who qualify have access at Smilow Cancer Hospital's Greenwich Hospital Campus to national clinical trials and research focusing on the latest treatment protocols and medications.
Research studies as of June, 2013
What are Clinical Trials?
NCIC MA.32: Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Center. Principal Investigator, Beverly Drucker, MD
ASBrS NSMR: American Society of Breast Surgeons Nipple Sparing Mastectomy Registry. Principal Investigator Barbara Ward, MD
Yale HIC #1112009465: Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults. Principal Investigator Beverly Drucker, MD
SWOG S1007: Phase III Randomized Trial of Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 (+) Nodes, Hormone Receptor (+) and HER2-Negative Breast Cancer with a Recurrence Score of 25 or Less. Principal Investigator Beverly Drucker, MD
Amgen 20110148: Randomized Single-Blinded Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Neulasta. Principal Investigator Beverly Drucker, MD
Breast Cancer Prevention
CALGB 70806: Trial Evaluating Vitamin D & Biomarkers for Breast Cancer Prevention in Premenopausal Women. Principal Investigator Barbara Ward, MD
CALGB C80702: Phase III Trial of 6 vs 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer. Principal Investigator Beverly Drucker, MD
NSABP P-5: Phase III Trial Using a Statin/Placebo to Prevent Polyps/Colon Cancer in Patients with Stage I-II Resected Colon Cancer. Principal Investigator Neal Schamberg, MD
CALGB 90601: A Placebo Randomized Study Comparing Gemcitabine, Cisplatin with or without Bevacizumab in Patients with Advanced Transitional Cell Carcinoma. Principal Investigator, Daniel Petrylak, MD.
ECOG E1505: Phase III Randomized Trial of Adjuvant Chemotherapy with/without Bevacizumab for patients with Completely Resected Stage IB-IIIA NSCLC. Principal Investigator, Beverly Drucker, MD
Lung Cancer Screening
I-ELCAP (International Early Lung Cancer Action Program) Lung Cancer Screening Trial Using Low Dose CT Scans. The study’s main objective is to learn whether the identification and early diagnosis of lung cancer leads to improvement in survival. For more information about the I-ELCAP study at Greenwich Hospital call 203-863-3698 or visit ielcap.org
. Principal Investigator David Mullen, MD
MLN C05013: Phase II Randomized Trial to Assess the Effectiveness of RCHOP with or without Velcade. Principal Investigator Beverly Drucker, MD
SWOG S1014: Phase II Trial to Assess the Effectiveness Abiraterone Acetate (Zytiga) Treatment for Prostate Cancer Patients with a PSA Greater than 4. Principal Investigator Daniel Petrylak, MD.
NOPR: National Oncologic PET Registry for Medicare Patients. Principal Investigator Chris Fey, MD
MagneMark Device Trial: Using a New Magnetic Breast Marking Wire to Localize Breast Lesions Needing Surgical Removal. Principal Investigator Barbara Ward, MD
Future Clinical Trials
Amgen 20110148: A Randomized Trial to Estimate the Effect of Patient Education on Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Neulasta. Principal Investigator Beverly Drucker, MD
Greenwich Hospital is a member of the national clinical research group Southwest Oncology Group (SWOG) enabling patients who qualify access to phase II and phase III clinical trials. Greenwich Hospital also participates in clinical trials initiated by the Yale Cancer Center. SWOG is sponsored by the National Cancer Institute. For more information about SWOG, visit www.swog.org
For more information
Contact clinical trials coordinators:
Jennie Melendez, RN